Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

Mayer KH, Venkatesh KK.

J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S122-7. doi: 10.1097/QAI.0b013e3181fbcb4c. Review.

2.

Human immunodeficiency virus postexposure prophylaxis for adolescents and children.

Merchant RC, Keshavarz R.

Pediatrics. 2001 Aug;108(2):E38.

PMID:
11483848
3.

Antiretroviral therapy as HIV prevention: status and prospects.

Mayer KH, Venkatesh KK.

Am J Public Health. 2010 Oct;100(10):1867-76. doi: 10.2105/AJPH.2009.184796. Epub 2010 Aug 19.

4.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932
5.

The essentials of HIV: a review for nurses.

Petroll AE, Hare CB, Pinkerton SD.

J Infus Nurs. 2008 Jul-Aug;31(4):228-35. doi: 10.1097/01.NAN.0000326831.82526.c4. Review.

6.

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Okwundu CI, Okoromah CA.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007189. doi: 10.1002/14651858.CD007189.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;7:CD007189.

PMID:
19160329
7.

The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.

Juusola JL, Brandeau ML, Owens DK, Bendavid E.

Ann Intern Med. 2012 Apr 17;156(8):541-50. doi: 10.7326/0003-4819-156-8-201204170-00001.

8.

Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.

Pinkerton SD, Holtgrave DR, Pinkerton HJ.

Arch Intern Med. 1997 Sep 22;157(17):1972-80.

PMID:
9308509
9.

Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.

Baker J, O╩╝Hara KM.

JAAPA. 2014 Dec;27(12):10-7. doi: 10.1097/01.JAA.0000456567.37724.e0. Review.

PMID:
25390822
10.

Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Myers GM, Mayer KH.

AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. Review.

PMID:
21284497
11.

Antiretrovirals for HIV prevention: when should they be recommended?

Kiselinova M, De Spiegelaere W, Verhofstede C, Callens SF, Vandekerckhove L.

Expert Rev Anti Infect Ther. 2014 Apr;12(4):431-45. doi: 10.1586/14787210.2014.896739. Review.

PMID:
24621251
12.

Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis.

Celum C, Baeten JM.

Antivir Ther. 2012;17(8):1483-93. doi: 10.3851/IMP2492. Epub 2012 Dec 7. Review.

13.

HIV exposure through contact with body fluids.

[No authors listed]

Prescrire Int. 2012 Apr;21(126):100-1, 103-5. Review.

PMID:
22515138
14.

Antiretroviral medication and HIV prevention: new steps forward and new questions.

Mayer KH, Krakower D.

Ann Intern Med. 2012 Feb 21;156(4):312-4. doi: 10.7326/0003-4819-156-4-201202210-00383. Epub 2012 Jan 16.

15.

Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.

Denton PW, Krisko JF, Powell DA, Mathias M, Kwak YT, Martinez-Torres F, Zou W, Payne DA, Estes JD, Garcia JV.

PLoS One. 2010 Jan 21;5(1):e8829. doi: 10.1371/journal.pone.0008829.

16.

Use of antiretrovirals for HIV prevention: what do we know and what don't we know?

Baeten JM, Grant R.

Curr HIV/AIDS Rep. 2013 Jun;10(2):142-51. doi: 10.1007/s11904-013-0157-9. Review.

17.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Mofenson LM; Centers for Disease Control and Prevention, U.S. Public Health Service Task Force.

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

18.

Nanotechnology-based systems for the treatment and prevention of HIV/AIDS.

das Neves J, Amiji MM, Bahia MF, Sarmento B.

Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):458-77. doi: 10.1016/j.addr.2009.11.017. Epub 2009 Nov 12. Review.

PMID:
19914314
19.

NextGen HIV prevention: new possibilities and questions.

Mayer KH.

Lancet. 2016 Mar 12;387(10023):1036-1038. doi: 10.1016/S0140-6736(16)00655-3. Epub 2016 Mar 4. No abstract available.

PMID:
26952545
20.

Post-exposure prophylaxis for HIV infection.

Rey D.

Expert Rev Anti Infect Ther. 2011 Apr;9(4):431-42. doi: 10.1586/eri.11.20. Review.

PMID:
21504400

Supplemental Content

Support Center